Claudia Berger

Claudia Berger is a proven expert in the field of clinical development and has been focusing on clinical trial operations and project management for more than 15 years. Before joining ImmunOs Therapeutics, she served as Director Clinical Operations at Inflazome Ltd, an Irish company recently acquired by Roche. Prior to that, she headed clinical operations at several biopharmaceutical companies such as Kinarus AG and Delenex Therapeutics, leading Phase I/II clinical programs, including profiling, biomarker and proof-of-concept studies with both biologics and small molecules and establishing quality assurance systems. From 2007 to 2012, she held several positions of increasing responsibility at the Novartis Institute for Biomedical Research (NIBR), most recently as Principal Clinical Scientist. Claudia Berger holds a Master of Science Degree in Pharmacy and a Diploma as a University Professional of Advanced Studies in Pharmaceutical Medicine.